Details of the Drug

General Information of Drug (ID: DMTIVEN)

Drug Name

Metronidazole

Synonyms

APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ

Indication

Disease Entry	ICD 11	Status	REF
Abscess	N.A.	Approved	[1]
Amoebiasis	1A36	Approved	[2]
Anaerobic bacteria infectious disease	N.A.	Approved	[1]
Bacteremia	1A73	Approved	[1]
Bacterial vaginosis	MF3A	Approved	[1]
Bladder squamous cell carcinoma	N.A.	Approved	[1]
Endometritis	N.A.	Approved	[1]
Liver abscess (disease)	N.A.	Approved	[1]
Peritonitis	N.A.	Approved	[1]
Trichomoniasis	N.A.	Approved	[1]
Crohn disease	DD70	Phase 3	[3]
Perianal crohn disease	DD70.4	Phase 3	[4]
Giardiasis	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiinfective Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

171.15

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 30-40 mg/L [5]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [5]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [7]
Clearance: The total clearance of drug is 2.1-6.4 L/h/kg [5]
Elimination: Metronidazole and its metabolites are 60 to 80% eliminated in the urine, and 6-15% excreted in the feces [8]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 10 h [5]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 194.55829 micromolar/kg/day [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.96% [10]
Vd: The volume of distribution (Vd) of drug is 0.51-1.1 L/kg [11]
Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [6]

Chemical Identifiers

Formula: C6H9N3O3
IUPAC Name: 2-(2-methyl-5-nitroimidazol-1-yl)ethanol
Canonical SMILES: CC1=NC=C(N1CCO)[N+](=O)[O-]
InChI: InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
InChIKey: VAOCPAMSLUNLGC-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4173
ChEBI ID: CHEBI:6909
CAS Number: 443-48-1
DrugBank ID: DB00916
TTD ID: D0A2ZX
INTEDE ID: DR1073
ACDINA ID: D00425

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Deoxyribonucleic acid (Bact DNA)	TTS1W4A	NOUNIPROTAC	Modulator	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[15]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[16]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[16]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[16]
Nitroreductase (NTR)	DEUW4J0	A0A376H6M5_ENTGA	Substrate	[17]
Nitroreductase (NTR)	DEP7ECA	B1R7B9_CLOPF	Substrate	[18]
Nitroreductase (NTR)	DEAN5EW	NFSB_ENTCL	Substrate	[19]
Nitroreductase (NTR)	DE3U2Y6	A0A377KR04_ENTCA	Substrate	[17]
Nitroreductase (NTR)	DEQGIMN	A4K8Z3_ENTHI	Substrate	[20]
Nitroreductase (NTR)	DE8R7QY	A0A482G3K9_GIAIN	Substrate	[20]
Nitroreductase (NTR)	DE2VSMT	A2DZ34_TRIVA	Substrate	[20]
Nitroreductase (NTR)	DELAPDY	A0A1C0X0J8_BACFG	Substrate	[21], [22]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Gene/Protein Processing	[23]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1)	OTRGGIFP	DRB1_HUMAN	Gene/Protein Processing	[23]
Interleukin-24 (IL24)	OT4VUWH1	IL24_HUMAN	Gene/Protein Processing	[24]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Gene/Protein Processing	[24]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Metronidazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Ivosidenib.	Acute myeloid leukaemia [2A60]	[25]
Midostaurin	DMI6E0R	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Midostaurin.	Acute myeloid leukaemia [2A60]	[25]
Idarubicin	DMM0XGL	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Idarubicin.	Acute myeloid leukaemia [2A60]	[25]
Arn-509	DMT81LZ	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Arn-509.	Acute myeloid leukaemia [2A60]	[25]
Gilteritinib	DMTI0ZO	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Gilteritinib.	Acute myeloid leukaemia [2A60]	[25]
Oliceridine	DM6MDCF	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Oliceridine.	Acute pain [MG31]	[25]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Metronidazole and Rivastigmine.	Alzheimer disease [8A20]	[26]
Bepridil	DM0RKS4	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Bepridil.	Angina pectoris [BA40]	[25]
Dronedarone	DMA8FS5	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Dronedarone.	Angina pectoris [BA40]	[25]
Bedaquiline	DM3906J	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[25]
Cilostazol	DMZMSCT	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Cilostazol.	Arterial occlusive disease [BD40]	[25]
Posaconazole	DMUL5EW	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Posaconazole.	Aspergillosis [1F20]	[25]
Salbutamol	DMN9CWF	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Salbutamol.	Asthma [CA23]	[27]
Lisdexamfetamine	DM6W8V5	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[25]
Desipramine	DMT2FDC	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[25]
Ofloxacin	DM0VQN3	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[26]
Sparfloxacin	DMB4HCT	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Gemifloxacin	DMHT34O	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Telithromycin	DMZ4P3A	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Telithromycin.	Bacterial infection [1A00-1C4Z]	[25]
Retigabine	DMGNYIH	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Retigabine.	Behcet disease [4A62]	[25]
Lapatinib	DM3BH1Y	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lapatinib.	Breast cancer [2C60-2C6Y]	[25]
Bosutinib	DMTI8YE	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Bosutinib.	Breast cancer [2C60-2C6Y]	[25]
PF-04449913	DMSB068	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[25]
Anisindione	DM2C48U	Major	Decreased metabolism of Metronidazole caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[28]
Halothane	DM80OZ5	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Halothane.	Corneal disease [9A76-9A78]	[25]
Sevoflurane	DMC9O43	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Sevoflurane.	Corneal disease [9A76-9A78]	[25]
Probucol	DMVZQ2M	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Probucol.	Coronary atherosclerosis [BA80]	[25]
Mycophenolic acid	DMRBMAU	Moderate	Altered absorption of Metronidazole due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[29]
Pasireotide	DMHM7JS	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Pasireotide.	Cushing syndrome [5A70]	[25]
Osilodrostat	DMIJC9X	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Osilodrostat.	Cushing syndrome [5A70]	[25]
Sertraline	DM0FB1J	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Sertraline.	Depression [6A70-6A7Z]	[25]
Escitalopram	DMFK9HG	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Escitalopram.	Depression [6A70-6A7Z]	[25]
Clomipramine	DMINRKW	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Clomipramine.	Depression [6A70-6A7Z]	[25]
Doxepin	DMPI98T	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Doxepin.	Depression [6A70-6A7Z]	[25]
Maprotiline	DMPWB7T	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Maprotiline.	Depression [6A70-6A7Z]	[25]
Tetrabenazine	DMYWQ0O	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[25]
Deutetrabenazine	DMUPFLI	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Deutetrabenazine.	Dystonic disorder [8A02]	[25]
Ingrezza	DMVPLNC	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Ingrezza.	Dystonic disorder [8A02]	[25]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Metronidazole caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Metronidazole caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Solifenacin	DMG592Q	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Solifenacin.	Functional bladder disorder [GC50]	[25]
Ketoconazole	DMPZI3Q	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Ketoconazole.	Fungal infection [1F29-1F2F]	[25]
Sunitinib	DMCBJSR	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[25]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Metronidazole caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[27]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Metronidazole caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Metronidazole and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[33]
Saquinavir	DMG814N	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Metronidazole and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Rilpivirine	DMJ0QOW	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Metronidazole caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[35]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Metronidazole caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[31]
Ceritinib	DMB920Z	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Ceritinib.	Lung cancer [2C25]	[25]
Osimertinib	DMRJLAT	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Osimertinib.	Lung cancer [2C25]	[25]
Selpercatinib	DMZR15V	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Selpercatinib.	Lung cancer [2C25]	[25]
Lumefantrine	DM29GAD	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lumefantrine.	Malaria [1F40-1F45]	[27]
Halofantrine	DMOMK1V	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Halofantrine.	Malaria [1F40-1F45]	[25]
Primaquine	DMWQ16I	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Primaquine.	Malaria [1F40-1F45]	[25]
Inotuzumab ozogamicin	DMAC130	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[25]
Arsenic trioxide	DM61TA4	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[25]
Vemurafenib	DM62UG5	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Vemurafenib.	Melanoma [2C30]	[25]
LGX818	DMNQXV8	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and LGX818.	Melanoma [2C30]	[25]
Panobinostat	DM58WKG	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Panobinostat.	Multiple myeloma [2A83]	[25]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Metronidazole and Thalidomide.	Multiple myeloma [2A83]	[34]
Siponimod	DM2R86O	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Siponimod.	Multiple sclerosis [8A40]	[25]
Fingolimod	DM5JVAN	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ozanimod	DMT6AM2	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Ozanimod.	Multiple sclerosis [8A40]	[25]
Romidepsin	DMT5GNL	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Romidepsin.	Mycosis fungoides [2B01]	[25]
Nilotinib	DM7HXWT	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Nilotinib.	Myeloproliferative neoplasm [2A20]	[25]
Dasatinib	DMJV2EK	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Dasatinib.	Myeloproliferative neoplasm [2A20]	[25]
Promethazine	DM6I5GR	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Promethazine.	Nausea/vomiting [MD90]	[25]
Entrectinib	DMMPTLH	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Entrectinib.	Non-small cell lung cancer [2C25]	[25]
Levomethadyl Acetate	DM06HG5	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Levomethadyl Acetate.	Opioid use disorder [6C43]	[27]
Lofexidine	DM1WXA6	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lofexidine.	Opioid use disorder [6C43]	[25]
Rucaparib	DM9PVX8	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Rucaparib.	Ovarian cancer [2C73]	[25]
Buprenorphine	DMPRI8G	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Buprenorphine.	Pain [MG30-MG3Z]	[25]
Triclabendazole	DMPWGBR	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Triclabendazole.	Parasitic worm infestation [1F90]	[25]
Pimavanserin	DMR7IVC	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Pimavanserin.	Parkinsonism [8A00]	[25]
Macimorelin	DMQYJIR	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[25]
Lefamulin	DME6G97	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lefamulin.	Pneumonia [CA40]	[25]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Metronidazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[36]
Degarelix	DM3O8QY	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Degarelix.	Prostate cancer [2C82]	[25]
ABIRATERONE	DM8V75C	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and ABIRATERONE.	Prostate cancer [2C82]	[25]
Enzalutamide	DMGL19D	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Enzalutamide.	Prostate cancer [2C82]	[25]
Relugolix	DMK7IWL	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Relugolix.	Prostate cancer [2C82]	[25]
Bicalutamide	DMZMSPF	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Bicalutamide.	Prostate cancer [2C82]	[25]
Levomepromazine	DMIKFEL	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Levomepromazine.	Psychotic disorder [6A20-6A25]	[25]
Gatifloxacin	DMSL679	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[25]
Quetiapine	DM1N62C	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Quetiapine.	Schizophrenia [6A20]	[25]
Mesoridazine	DM2ZGAN	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Mesoridazine.	Schizophrenia [6A20]	[25]
Aripiprazole	DM3NUMH	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Aripiprazole.	Schizophrenia [6A20]	[25]
Iloperidone	DM6AUFY	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Iloperidone.	Schizophrenia [6A20]	[25]
Paliperidone	DM7NPJS	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Paliperidone.	Schizophrenia [6A20]	[25]
Amisulpride	DMSJVAM	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Amisulpride.	Schizophrenia [6A20]	[25]
Asenapine	DMSQZE2	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Asenapine.	Schizophrenia [6A20]	[25]
Pimozide	DMW83TP	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Pimozide.	Schizophrenia [6A20]	[25]
LEE011	DMMX75K	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[25]
Vandetanib	DMRICNP	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[25]
Triptorelin	DMTK4LS	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Doxorubicin	DMVP5YE	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Pitolisant	DM8RFNJ	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Pitolisant.	Somnolence [MG42]	[25]
Telavancin	DM58VQX	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[25]
Lenvatinib	DMB1IU4	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Lenvatinib.	Thyroid cancer [2D10]	[25]
Cabozantinib	DMIYDT4	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Cabozantinib.	Thyroid cancer [2D10]	[25]
Trimeprazine	DMEMV9D	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[27]
Procainamide	DMNMXR8	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Procainamide.	Ventricular tachyarrhythmia [BC71]	[25]
Propafenone	DMPIBJK	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Propafenone.	Ventricular tachyarrhythmia [BC71]	[25]
Flecainide	DMSQDLE	Minor	Increased risk of prolong QT interval by the combination of Metronidazole and Flecainide.	Ventricular tachyarrhythmia [BC71]	[25]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Metronidazole caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[37]
-----------


⏷ Show the Full List of 112 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Hydroxystearic acid	E00367	69417	Other agent
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium stearoyl lactylate	E00558	23671849	Emulsifying agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Metronidazole 375 mg capsule	375 mg	Oral Capsule	Oral
Metronidazole 250 mg tablet	250 mg	Oral Tablet	Oral
Metronidazole 500 mg tablet	500 mg	Oral Tablet	Oral
Metronidazole 750 mg tablet	750 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Metronidazole FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018517.
3	ClinicalTrials.gov (NCT00509639) Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Canadian monograph, Flagyl
6	BDDCS applied to over 900 drugs
7	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
8	Lamp KC, Freeman CD, Klutman NE, Lacy MK: Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999 May;36(5):353-73. doi: 10.2165/00003088-199936050-00004.
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11	Hernandez Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, Lopez Contreras L: Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):397-401. doi: 10.26355/eurrev_201901_16788.
12	DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8.
13	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother. 2007 Apr;41(4):653-8.
14	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
15	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
16	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
17	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
18	Acetamide--a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol. 1979 Dec 15;28(24):3611-5.
19	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
20	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
21	Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State. J Clin Microbiol. 2004 Sep;42(9):4127-9. Case Reports
22	Biotransformation of 1-nitropyrene in intestinal anaerobic bacteria. Microbiol Immunol. 1982;26(11):993-1005.
23	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
24	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
25	Cerner Multum, Inc. "Australian Product Information.".
26	Canadian Pharmacists Association.
27	Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983): 509-15. [PMID: 6668631]
28	Dean RP, Talbert RL "Bleeding associated with concurrent warfarin and metronidazole therapy." Drug Intell Clin Pharm 14 (1980): 864-6.
29	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
30	Blyden GT, Scavone JM, Greenblatt DJ "Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam." J Clin Pharmacol 28 (1988): 240-5. [PMID: 3360972]
31	Gupte S "Phenobarbital and metabolism of metronidazole." N Engl J Med 308 (1983): 529. [PMID: 6823276]
32	Product Information. Tindamax (tinidazole). Presutti Laboratories Inc, Arlington Heights, IL.
33	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
34	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
35	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
36	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
37	Haas CE, Kaufman DC, DiCenzo RC "Effects of metronidazole on hepatic CYP3A4 activity." Pharmacotherapy 21 (2001): 1192-5. [PMID: 11601665]